GGrantIndex
← Leaderboards

Kwame Osei

Ohio State University

$754,133
Attributed
$754,133
Total exposure
10
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $16.6K · FY200508
$20K$15K$10K$5K$0
'05
'06
'07
'08

Funding mix

By agency

NIH$754,133 · 10

By mechanism

M01$754,133 · 10

Top collaborators

No co-investigators on record.

Most similar at Ohio State University

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchHuman Therapy EvaluationHuman SubjectInsulinDiabetes Mellitus TherapyAfrican AmericanNoninsulin Dependent Diabetes MellitusBiomarkerChemopreventionInsulin Dependent Diabetes MellitusInsulin Sensitivity /ResistanceUnited States National Institutes Of HealthInstitutionResearch PersonnelResourcesFundingInsulin SensitivityGrantComputer Retrieval Of Information On Scientific Projects DatabaseSourceFamily GeneticsAmericanHypoglycemic AgentsAdiponectin

Grant awards (19)

EFFECTS OF RACE/ETHNICITY ON ADIPONECTIN LEVELS AND INSULIN ACTION$2,079
M01 · FY2008 · RR · contact PI
ADIPONECTIN IN PERSONS OF WEST AFRICAN ANCESTRY$693
M01 · FY2008 · RR · contact PI
GLUCOSE HOMEOSTASIS AND LIPID PATTERNS IN PATIENTS WITH TYPE 1 DIABETES 10 YEARS$15,409
M01 · FY2007 · RR · contact PI
ADIPONECTIN IN PERSONS OF WEST AFRICAN ANCESTRY$1,233
M01 · FY2007 · RR · contact PI
GLUCOSE HOMEOSTASIS AND LIPID PATTERNS IN PATIENTS WITH TYPE 1 DIABETES 10 YEARS$2,568
M01 · FY2006 · RR · contact PI
GLUCOSE HOMEOSTASIS AND LIPID PATTERNS IN PATIENTS WITH TYPE 1 DIABETES 10 YEARS$4,669
M01 · FY2005 · RR
DIABETES PREVENTION TRIAL--TYPE I DIABETES (DPT-1)$193,916
M01 · FY2001 · RR
ANTIDIABETIC AGENTS AS PROPHYLAXIS IN PREVENTION OF NIDDM IN AFRICAN AMERICANS$193,916
M01 · FY2001 · RR
ENDOCRINE EVALUATION OF PANCREATIC TRANSPLANT$193,916
M01 · FY2001 · RR
ANTIDIABETIC AGENTS AS PROPHYLAXIS IN PREVENTION OF NIDDM IN AFRICAN AMERICANS$48,578
M01 · FY2000 · RR
DIABETES PREVENTION TRIAL--TYPE I DIABETES (DPT-1)$48,578
M01 · FY2000 · RR
ENDOCRINE EVALUATION OF PANCREATIC TRANSPLANT$48,578
M01 · FY2000 · RR
EFFICACY OF REPAGLINIDE ALONE AND/OR IN COMBINATION WITH METFORMIN$0
M01 · FY2000 · RR
EFFICACY OF REPAGLINIDE ALONE AND/OR IN COMBINATION WITH METFORMIN$0
M01 · FY2000 · RR
COMPARISON OF ONCE DAILY NN304 AND ONCE DAILY NPH INSULIN TREATMENT IN NIDDM$0
M01 · FY2000 · RR
COMPARISON OF ONCE DAILY NN304 AND ONCE DAILY NPH INSULIN TREATMENT IN NIDDM$0
M01 · FY2000 · RR
ENDOCRINE EVALUATION OF PANCREATIC TRANSPLANT$0
M01 · FY2000 · RR
DIABETES PREVENTION TRIAL--TYPE I DIABETES (DPT-1)$0
M01 · FY2000 · RR
ANTIDIABETIC AGENTS AS PROPHYLAXIS IN PREVENTION OF NIDDM IN AFRICAN AMERICANS$0
M01 · FY2000 · RR